FDG PET/MRI 融合有助于预测脑转移瘤患者对伽玛刀放射外科治疗的反应
本研究回顾性分析85例非中枢神经系统肿瘤脑转移患者的影像与临床资料,这些患者接受伽玛刀放射外科治疗后因MRI发现可疑进展而行FDG PET检查,并将PET与增强MRI融合。结果显示,相对SUV与局部肿瘤控制显著相关(p=0.035),诊断局部进展的ROC AUC为0.67(95% CI,0.55-0.79)。作者认为,治疗后FDG PET定量相对SUV可作为SRS反应的生物标志物,可能影响管理决策。
要点
- 治疗后FDG PET/MRI融合测量的相对SUV与脑转移瘤SRS后局部控制显著相关(p=0.035)。
- 相对SUV鉴别局部进展的ROC AUC为0.67(95% CI,0.55-0.79)。
- 在随访MRI发现病灶增大时,相对SUV可能帮助区分进展与治疗效应。
核心结论
- 治疗后FDG PET定量相对SUV可作为脑转移瘤患者SRS反应的生物标志物,尤其在随访MRI发现病灶生长时;该预后数据可能影响管理,支持对部分患者采取进一步治疗措施。
研究设计与样本
- 回顾性研究,纳入85例来自非中枢神经系统肿瘤的脑转移患者(48例女性[56.5%],37例男性[43.5%],诊断时平均年龄60.5±11.3岁),均接受伽玛刀放射外科治疗并因MRI可疑进展而行治疗后FDG PET;将PET与增强MRI融合,由两名独立阅片者基于SRS完成后至少3个月的系列MRI评估反应。
关键影像表现/征象
- 相对SUV定义为肿瘤内最大SUV与对侧表现正常白质最大SUV的比值,ROI置于强化病灶内FDG摄取最高区。
- 33个(38.8%)病灶在SRS后进展。
- 相对SUV与局部肿瘤控制显著相关(p=0.035)。
诊断标准与关键数值
- 相对SUV预测局部肿瘤进展的ROC AUC为0.67(95% CI,0.55-0.79)。
临床应用与阅片要点
- 在随访MRI发现病灶增大时,可参考治疗后FDG PET/MRI融合测得的相对SUV辅助判断SRS后局部肿瘤进展风险。
- 作者认为该预后数据可能影响管理,支持对部分患者采取进一步治疗措施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The purpose of this study was to determine whether relative standardized uptake value (SUV) measurements at FDG PET/MRI coregistration are predictive of local tumor control in patients with brain metastases treated with stereotactic radiosurgery (SRS).
MATERIALS AND METHODS: A retrospective review was conducted of the images and clinical characteristics of a cohort of patients with brain metastases from non-CNS neoplasms treated with gamma knife radiosurgery (GKRS) who underwent posttherapy FDG PET because of MRI findings concerning for progression. The PET and contrast-enhanced MR images were fused. Relative SUV measurements were calculated from ROIs placed in the area of highest FDG uptake within the enhancing lesion and in the contralateral normal-appearing white matter. Relative SUV was defined as the ratio of maximum SUV in the tumor to maximum SUV in healthy white matter. Two independent readers evaluated response to GKRS using serial posttherapy MRI performed at least 3 months after GKRS completion. The relation between relative SUV and local tumor progression was evaluated with respect to treatment effect.
RESULTS: Eighty-five patients (48 [56.5%] women, 37 [43.5%] men; mean age at diagnosis, 60.5 ± 11.3 years) met the inclusion criteria. Thirty-three (38.8%) lesions progressed after SRS. There was a significant association between relative SUV and local tumor control (p = 0.035). Relative SUV provided a diagnostic ROC AUC of 0.67 (95% CI, 0.55-0.79).
CONCLUSION: Quantitative relative SUV at posttherapy FDG PET serves as a biomarker of response to SRS in patients with brain metastases in cases in which lesion growth is identified at follow-up MRI. This prognostic data may affect management, supporting the need for further therapeutic actions for selected patients.
引用
- Leiva-Salinas C, Muttikkal TJE, Flors L, et al. FDG PET/MRI Coregistration Helps Predict Response to Gamma Knife Radiosurgery in Patients With Brain Metastases. AJR Am J Roentgenol. 2018. PMID: 30422717. doi:10.2214/AJR.18.20006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。